Temozolomide & Treatment
of Brain Metastases
Use
of Temozolomide with Other Chemotherapy in Patients with Recurrent Brain
Metastases from Lung Cancer (The Oncologist)
by Ebert, BL et al.
v.8, no.1 The Oncologist (February 2003): 69-75
Discusses the use of temozolomide with other chemotherapeutic agents
as a promising strategy for treating lung cancer patients with recurrent
brain metastases. [1/03]
Temozolomide
in Patients with Advanced NSCLC with and without Brain Metastases: a Phase
II Study of the EORTC Lung Cancer Group (PubMed)
Abstract of a study reported in the June 2003 issue of the European
Journal of Cancer that evaluated the activity of single-agent temozolomide
in two groups of chemotherapy-naive NSCLC patients with (12 patients)
and without (13 patients) brain metastases. Reports that no objective
response was observed in either group and the study was closed after the
first step of accrual with the conclusion of a lack of therapeutic activity
of single-agent temozolomide in patients with stage IV NSCLC. [6/03]
Temozolomide
Improves Response of Brain Metastases to Radiation Therapy
(Doctor's Guide)
Summarizes the results of a Phase III study presented at the 2002
annual meeting of the American Society for Therapeutic Radiology and Oncology
(ASTRO) that found that adding temozolomide to whole brain radiation therapy
significantly increases the response rate of patients with brain metastases.
Of the 134 patients in the study, 82% had lung cancer as their primary
site. [10/02]
Temozolomide
& Treatment of Brain Metastases - Recent MEDLINE Abstracts
Temozolomide & Treatment of NSCLC
Temozolomide
in Patients with Advanced NSCLC with and without Brain Metastases: a Phase
II Study of the EORTC Lung Cancer Group (PubMed)
Abstract of a study reported in the June 2003 issue of the European
Journal of Cancer that evaluated the activity of single-agent temozolomide
in two groups of chemotherapy-naive NSCLC patients with (12 patients)
and without (13 patients) brain metastases. Reports that no objective
response was observed in either group and the study was closed after the
first step of accrual with the conclusion of a lack of therapeutic activity
of single-agent temozolomide in patients with stage IV NSCLC. [6/03]
Temozolomide
& Treatment of NSCLC - Recent MEDLINE Abstracts
Temozolomide - Side Effects
Temodar (temozolomide)
(Schering)
Manufacturer's patient guide answers frequently-asked questions
about Temodar (temozolomide).
Temozolomide Clinical
Trials
Temozolomide
and Brain Metastases - Clinical Trials (ClinicalTrials.gov)
|
